The prognostic value of TP53 mutational status in children with Burkitt lymphoma treated according to the B-NHL-2010M protocol

Cover Page

Cite item

Full Text

Abstract

   Burkitt lymphoma (BL) is one of the most common types of non-Hodgkin lymphoma in children. The application of modern risk-adapted treatment regimens has resulted in 85–90 % survival rates in affected patients; however, prognosis still remains poor in case of relapsed/refractory disease. In standard protocols, patients were stratified into risk groups based primarily on disease stage and extent and lactate dehydrogenase levels. Mutations in the TP53 gene are associated with a poor prognosis in many tumors, and lately there have been reports that TP53 status may have prognostic value in pediatric BL. We analyzed therapy outcomes in patients treated in accordance with the B-NHL-2010M protocol according to their TP53 mutational status. We discovered that the 5-year event-free and overall survival rates in the patients with TP53 mutations were 45.3 % and 47.1 % respectively, versus 97.9% and 97.9% in those without TP53 mutations (p < 0.001). Hence, TP53 mutational status is an important prognostic marker in pediatric patients with BL and should be utilized in future protocols. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.

About the authors

E. V. Volchkov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation; Research Institute of Molecular and Cellular Medicine of the Patrice Lumumba Рeoples’ Friendship University of Russia

Author for correspondence.
Email: volchcov.egor@yandex.ru
ORCID iD: 0000-0002-2574-1636

Egor V. Volchkov, a hematologist

Lymphoma Research Department

117997; 1 Samory Mashela St.; Moscow

Russian Federation

Yu. G. Abugova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: Yuliya.Abugova@fccho-moscow.ru

Moscow

Russian Federation

K. R. Brenning

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: karina.brening@fccho-moscow.ru

Moscow

Russian Federation

D. S. Abramov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: abramovd_s@bk.ru

Moscow

Russian Federation

V. V. Fominykh

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: Veronica.Fomynih@fccho-moscow.ru

Moscow

Russian Federation

M. A. Senchenko

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: senchenko.mariia@yandex.ru

Moscow

Russian Federation

L. Kh. Chugaeva

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: anderliliya@gmail.com

Moscow

Russian Federation

Yu. V. Olshanskaya

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: yuliya.olshanskaya@fccho-moscow.ru
ORCID iD: 0000-0002-2352-7716

Moscow

Russian Federation

G. A. Novichkova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: Galina.Novichkova@fccho-moscow.ru
ORCID iD: 0000-0002-2322-5734

Moscow

Russian Federation

N. V. Myakova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Email: nmiakova@mail.ru
ORCID iD: 0000-0002-4779-1896

Moscow

Russian Federation

References

  1. Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., de Oliveira Araujo I.B., Berti E., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36 (7): 1720–48. doi: 10.1038/s41375-022-01620-2
  2. Thacker N., Abla O. Epidemiology of Non-Hodgkin Lymphomas in Childhood and Adolescence. In: Abla, O., Attarbaschi, A. (eds) Non-Hodgkin's Lymphoma in Childhood and Adolescence. Springer, Cham; 2019. doi: 10.1007/978-3-030-11769-6_2.
  3. Patte C., Auperin A., Michon J., Behrendt H., Leverger G., Frappaz D., et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97 (11): 3370–9. doi: 10.1182/blood.v97.11.3370
  4. Jourdain A., Auperin A., Minard-Colin V., Aladjidi N., Zsiros J., Coze C., et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l'Enfant study. Haematologica 2015; 100 (6): 810–7. doi: 10.3324/haematol.2014.121434
  5. Woessmann W., Zimmermann M., Meinhardt A., Müller S., Hauch H., Knörr F., et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood 2020; 135 (14): 1124–32. doi: 10.1182/blood.2019003591
  6. Samochatova E., Maschan A., Shelikhova L., Myakova N.V., Belogurova M.B., Khlebnikova O.P., et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenterstudy. J Pediatr Hematol Oncol 2014; 36 (5): 395–401. doi: 10.1097/MPH.0b013e31829d4900
  7. Minard-Colin V., Aupérin A., Pillon M., Amos Burke G.A., Barkauskas D.A., Wheatley K., et al. European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 2020; 382 (23): 2207–19. doi: 10.1056/NEJMoa1915315
  8. Maschan A., Myakova N., Aleinikova O., Abugova Yu., Ponomareva N., Belogurova M., et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian–Belorussian multicentre study B-NHL-2010M. Br J Haematol 2019; 186 (3): 477–83. doi: 10.1111/bjh.15944
  9. Love C., Sun Z., Jima D., Li G., Zhang J., Miles R., et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44 (12): 1321–5. doi: 10.1038/ng.2468
  10. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2 (1): a001008. doi: 10.1101/cshperspect.a001008
  11. Rowh M., DeMicco A., Horowitz J., Yin B., Yang-Iott K.S., Fusello A.M., et al. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations. Oncogene 2011; 30 (47): 4757–64. doi: 10.1038/onc.2011.191
  12. Xu-Monette Z., Medeiros L., Li Y., Orlowski R.Z., Andreeff M., Bueso-Ramos C.E., et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012; 119 (16): 3668–83. doi: 10.1182/blood-2011-11-366062
  13. Leventaki V., Rodic V., Tripp S., Bayerl M.G., Perkins S.L., Barnette P., et al. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Br J Haematol 2012; 158 (6): 763–71. doi: 10.1111/j.1365-2141.2012.09243.x
  14. Lacy S., Barrans S., Beer P., Painter D., Smith A.G., Roman E., et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 2020; 135 (20): 1759–71. doi: 10.1182/blood.2019003535
  15. Xu-Monette Z., Wu L., Visco C., Tai Y.C., Tzankov A., Liu W., et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012; 120 (19): 3986–96. doi: 10.1182/blood-2012-05-433334
  16. Zenz T., Kreuz M., Fuge M., Klapper W., Horn H., Staiger A.M., et al. TP53 mutation and survival in aggressive B cell lymphoma. Int J Cancer 2017; 141 (7): 1381–8. doi: 10.1002/ijc.30838
  17. Newman A., Zaka M., Zhou P., Blain A.E., Erhorn A., Barnard A., et al. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia 2022; 36 (3): 781–9. doi: 10.1038/s41375-021-01444-6
  18. Srinivasan S., Roy Moulik N., Kc A., Narula G., Sankaran H., Prasad M., et al. Increased toxicities in children with Burkitt lymphoma treated with rituximab: experience from a tertiary cancer center in India. Pediatr Blood Cancer 2020; 67 (11): e28682. doi: 10.1002/pbc.28682
  19. Ehrhardt M., Chen Y., Sandlund J., Bluhm E.C., Hayashi R.J., Becktell K., et al. Late health outcomes after contemporary lymphome Malin de Burkitt therapy for mature B-Cell Non-Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol: Off J Am Soc Clin Oncol 2019; 37 (28): 2556–70. doi: 10.1200/JCO.19.00525
  20. Attarbaschi A., Carraro E., Ronceray L., Andrés M., Barzilai-Birenboim S., Bomken S., et al. Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma-a retrospective multinational study of 189 children and adolescents. Leukemia 2020; 35 (2): 534–49. doi: 10.1038/s41375-020-0841-x
  21. Panea R., Love C., Shingleton J., Reddy A., Bailey J.A., Moormann A.M., et al. The whole genome landscape of Burkitt lymphoma subtypes. Blood 2019; 134 (19): 1598–607. doi: 10.1182/blood.2019001880
  22. Grande B., Gerhard D., Jiang A., Griner N.B., Abramson J.S., Alexander T.B., et al. Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 2019; 133 (12): 1313–24. doi: 10.1182/blood-2018-09-871418
  23. Griesmann H., Schlereth K., Krause M., Samans B., Stiewe T. p53 and p73 in suppression of Mycdriven lymphomagenesis. Int J Cancer 2009; 124 (2): 502–6. doi: 10.1002/ijc.23978
  24. Yu L., Yu T., Young K. Cross-talk between Myc and p53 in B-cell lymphomas. Chronic Dis Transl Med 2019; 5 (3): 139–54. doi: 10.1016/j.cdtm.2019.08.001

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Volchkov E.V., Abugova Y.G., Brenning K.R., Abramov D.S., Fominykh V.V., Senchenko M.A., Chugaeva L.K., Olshanskaya Y.V., Novichkova G.A., Myakova N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.